Business Context and Reporting Period
Acrivon Therapeutics, Inc. (ACRV), a Delaware corporation, filed a Current Report on Form 8-K dated January 8, 2026. The filing serves as a Regulation FD disclosure regarding a corporate webcast and conference call held on the same date. The Company is an emerging growth company focused on clinical development, specifically highlighting updates for its programs ACR-368 and ACR-2316.
Key Financial Metrics
This filing is a non-financial event report and does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes
The filing does not report material changes to financial position or operations. The primary material event is the release of new clinical data and program updates via a data presentation titled the "January 8, 2026 Data Update."
Guidance, Outlook, and Management Commentary
- Event Details: The Company hosted a webcast and Q&A session from 8:30 a.m. to 9:00 a.m. ET on January 8, 2026.
- Content: The presentation included clinical data for ACR-368, program updates, and initial clinical data for ACR-2316.
- Availability: The presentation is available on the Company's website under the "Investors & Media" section and is attached as Exhibit 99.1.
- Legal Status: The information in this Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific clinical data points for ACR-368 and ACR-2316 in the attached Exhibit 99.1 ("January 8, 2026 Data Update").
- Review the Company's website (ir.acrivon.com) for the full presentation and any accompanying press releases.
- Confirm the Company's cash runway and liquidity status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor future filings for any regulatory decisions or trial outcomes resulting from the data presented.